MedTrace Logo

Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure

NCT00902915 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-11-25

No results posted yet for this study

Summary

The purpose of this study is to determine efficacy of lenalidomide and dexamethasone in the treatment of patients with acute Myeloma (light chain)-induced renal failure.

Conditions

  • Multiple Myeloma Light Chain Induced Renal Insufficiency

Interventions

DRUG

lenalidomide plus dexamethasone

peroral application; lenalidomide dosage according to severity grade of renal failure.

Sponsors & Collaborators

  • Austrian Forum Against Cancer

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Austria
  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00902915 on ClinicalTrials.gov